Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00748163
Other study ID # 2007LS098
Secondary ID 0802M26201ABX080
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date August 2008
Est. completion date August 2008

Study information

Verified date August 2018
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel albumin-stabilized nanoparticle formulation together with sunitinib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving paclitaxel albumin-stabilized nanoparticle formulation together with sunitinib works as first-line therapy in treating patients with stage IV non-small cell lung cancer.


Description:

OBJECTIVES:

Primary

- To determine the tumor response rate in patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.

Secondary

- To determine the time to objective tumor response and duration of response in responding patients.

- To determine the time to treatment failure and overall survival of these patients.

- To characterize the toxicities of this regimen in these patients.

OUTLINE: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed every 8 weeks until disease progression and then every 3 months for up to 1 year.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 2008
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

- Stage IV disease

- At least 1 measurable lesion as defined by modified RECIST criteria

- No symptomatic or untreated brain metastases

- Prior brain metastases allowed provided the CNS disease has been treated and is considered stable and the patient has recovered from the acute toxic effects of the treatment prior to study entry

PATIENT CHARACTERISTICS:

Inclusion criteria:

- ECOG performance status 0-1

- WBC = 3.0 x 10^9/L

- ANC = 1.5 x 10^9/L

- Platelet count = 100 x 10^9/L

- Bilirubin = 1.5 mg/dL

- AST and ALT = 2.5 times upper limit of normal (ULN) (= 5 times ULN if liver has tumor involvement)

- Creatinine = 1.5 mg/dL

- LVEF = 40% by MUGA

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after completion of study treatment

Exclusion criteria:

- Congestive heart failure, myocardial infarction, or coronary artery bypass graft within the past 12 months

- Ongoing severe or unstable angina

- Unstable arrhythmia requiring medication

- Sensory neuropathy = grade 2 (according to NCI CTCAE v3.0)

- Known hypersensitivity to any of the agents used in this study

- Serious medical or psychiatric illness that, in the opinion of the enrolling investigator, is likely to interfere with study participation

PRIOR CONCURRENT THERAPY:

- No prior systemic therapy for NSCLC

- More than 4 weeks since prior major surgery

- More than 7 days since prior and no concurrent potent CYP3A4 inhibitors, including any of the following:

- Ketoconazole

- Itraconazole

- Clarithromycin

- Erythromycin

- Diltiazem

- Verapamil

- Delavirdine

- Indinavir

- Saquinavir

- Ritonavir

- Atazanavir

- Nelfinavir

- More than 12 days since prior and no concurrent potent CYP3A4 inducers, including any of the following:

- Rifampin

- Rifabutin

- Carbamazepine

- Phenobarbital

- Phenytoin

- St. John's wort

- Efavirenz

- Tipranavir

- No concurrent treatment with a drug having proarrhythmic potential, including any of the following:

- Terfenadine

- Quinidine

- Procainamide

- Disopyramide

- Sotalol

- Probucol

- Bepridil

- Haloperidol

- Risperidone

- Indapamide

- Flecainide

- No other concurrent investigational agents

Study Design


Intervention

Drug:
paclitaxel albumin-stabilized nanoparticle formulation

sunitinib malate


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate 1 Year
Secondary Time to objective tumor response as assessed by RECIST criteria 1 Year
Secondary Duration of response 1 Year
Secondary Time to treatment failure 1 Year
Secondary Overall survival 1 Year
Secondary Toxicity and adverse events as assessed by NCI CTCAE v3.0 1 Year
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk